TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30328302
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser plus Sodium Fluoride (L+NaF)
Study: 30328302
Drug: Other treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatments (CPP-ACPF, HA-NaF-X, L+CPP-ACPF, L+HA-NaF-X)
Study: 14604742
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg BID
Study: 14604742
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg BID (adjusted for noncompliance)
Study: 14604742
Drug: Discontinuing fluvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuing fluvastatin without switching to another lipid‐lowering medication
Study: 10685657
Drug: IL-2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 therapy (9 million IU/m2/d for 4 days, then 1.6 million IU/m2/d for 10 days)
Study: 9514403
Drug: High-dose multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose multivitamin supplements containing 5 mg folic acid, 0.4 mg hydroxycobalamin, and 50 mg pyridoxine
Study: 9514403
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg folic acid
Study: 3135934
Drug: Carboplatin in
Normalized name: Carboplatin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin in combination with cyclophosphamide, doxorubicin, and hexamethylmelamine
Study: 3135934
Drug: Cisplatin in
Normalized name: cisplatin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin in combination with cyclophosphamide, doxorubicin, and hexamethylmelamine
Study: 28185997
Drug: Vilaprisan (2mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan (2mg daily) for 12 or 24 weeks, or two 12-week treatment periods separated by a break to allow one menstruation to occur.
Study: 28185997
Drug: Ulipristal acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ulipristal acetate (5mg daily) for 12 weeks.
Study: 28185997
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 12 weeks followed by active treatment for 12 weeks.
Study: 28185997
Drug: Vilaprisan (2mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan (2mg daily) in different regimens.
Study: 26248820
Drug: No antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiplatelet medication
Study: 20221953
Drug: Computerized aphasia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized aphasia treatment
Study: 20221953
Drug: Phase 3
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase 3 study of computerized aphasia treatment
Study: 18171452
Drug: Open-label conditioned
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label conditioned placebo dose reduction (CPDR) treatment
Study: 14644721
Drug: Anecortave acetate
Normalized name: Anecortave acetate
DrugBank: Anecortave (DB12081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anecortave acetate (15 mg)
Study: 31386583
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily practice only)
Study: 15608030
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive containing 20 microg di EE and 150 microg of desogestrel (group B)
Study: 12200684
Drug: Reinforced courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforced courses of chemotherapy (standard 3+7 including high-dose daunorubicin, double induction, and timed-sequential therapy)
Study: 12200684
Drug: Reinforced courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforced courses of chemotherapy
Study: 7572320
Drug: Oral dimethyl-APD
Normalized name: dimethyl fumarate Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dimethyl-APD (100-400 mg/day)
Study: 7572320
Drug: Intravenous dimethyl-APD
Normalized name: Dimethyl sulfone
DrugBank: Dimethyl sulfone (DB14090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dimethyl-APD (4 mg/day)
Study: 2142705
Drug: Early thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early thrombolytic therapy (administered at 7 hours)
Study: 2142705
Drug: Late thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late thrombolytic therapy (administered at 11 hours)
Study: 2142705
Drug: Late thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late thrombolytic therapy (administered at 17 hours)
Study: 2142705
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (timing not specified)
Study: 508503
Drug: Temazepam 20
Normalized name: temazepam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 20 mg (Scherer formulation)
Study: 508503
Drug: Amylobarbitone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amylobarbitone 100 mg
Study: 25591053
Drug: Therapeutic Tai
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic Tai Chi (10 different movements, 60 min, twice per week, for 6 weeks)
Study: 22397261
Drug: Intravenous patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient controlled analgesia (PCA) with morphine
Study: 8405642
Drug: amoxycillin/clavulanate (AMX/CL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxycillin/clavulanate (AMX/CL) 2200 mg i.v. as a single dose
Study: 8405642
Drug: cefuroxime plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefuroxime plus metronidazole (CR/MN) 750/500 mg i.v. administered 3 times within 24 h
Study: 30829460
Drug: Intervention Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Group (IG) - 1 year phoned physical activity advice individually adapted to physical assessment (twice a month during the first 6 months and then monthly)
Study: 29477692
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg or 2.0 mg monthly or pro re nata (PRN)
Study: 29477692
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment (monthly vs PRN)
Study: 24456373
Drug: CERA administered
Normalized name: CERA
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CERA administered intravenously at weeks 0 and 2 (TWICE group)
Study: 24456373
Drug: CERA administered
Normalized name: CERA
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CERA administered intravenously at week 0 (ONCE group)
Study: 22156314
Drug: Landiolol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (3 µg·kg(‐1)·min(‐1) for 24 h)
Study: 22156314
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no landiolol administration)
Study: 20167278
Drug: Defibrotide 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide 25 mg/kg/day (arm A)
Study: 20167278
Drug: Defibrotide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide 40 mg/kg/day (arm B)
Study: 2328959
Drug: Ethanol (10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (10% solution in 5% dextrose in water)
Study: 7016402
Drug: L-valine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-valine (600 mumol/min)
Study: 7016402
Drug: L-isoleucine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-isoleucine (150 mumol/min)
Study: 7016402
Drug: L-leucine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-leucine (300 mumol/min)
Study: 7016402
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of branched-chain amino acids (70% L-leucine, 20% L-valine, 10% L-isoleucine; 270 mumol/min)
Study: 27862308
Drug: Alemtuzumab consolidation
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab consolidation therapy
Study: 16267908
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy and local-regional radiotherapy
Study: 10526275
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with cisplatin plus etoposide (n = 12)
Study: 10526275
Drug: Concurrent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent therapy with cisplatin plus etoposide (n = 18)
Study: 29660295
Drug: Infants' birth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants' birth weight less than 2,300 g
Study: 12514410
Drug: Atazanavir 200
Normalized name: atazanavir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir 200 mg once daily
Study: 12514410
Drug: Atazanavir 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir 500 mg once daily
Study: 12514410
Drug: Nelfinavir 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir 750 mg three times daily
Study: 10378564
Drug: MDI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI with small volume spacer (5 puffs, 450 microg albuterol)
Study: 10378564
Drug: Nebulizer (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizer (2.5 mg albuterol)
Study: 10378564
Drug: MDI port
Normalized name: My MDI Portable Nebuliser
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI port on right-angle adaptor (5 puffs, 450 microg albuterol)
Study: 8686821
Drug: Neostigmine 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.04 mg.kg‐1 with atropine 0.02 mg.kg‐1
Study: 7471605
Drug: Indacrinone (−)
Normalized name: Inamrinone
DrugBank: Amrinone (DB01427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indacrinone (−) enantiomer 10 mg with (+) enantiomer 0 mg (10/0)
Study: 7471605
Drug: Indacrinone (−)
Normalized name: Inamrinone
DrugBank: Amrinone (DB01427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indacrinone (−) enantiomer 10 mg with (+) enantiomer 10 mg (10/10)
Study: 7471605
Drug: Indacrinone (−)
Normalized name: Inamrinone
DrugBank: Amrinone (DB01427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indacrinone (−) enantiomer 10 mg with (+) enantiomer 20 mg (10/20)
Study: 7471605
Drug: Indacrinone (−)
Normalized name: Inamrinone
DrugBank: Amrinone (DB01427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indacrinone (−) enantiomer 10 mg with (+) enantiomer 40 mg (10/40)
Study: 7471605
Drug: Indacrinone (−)
Normalized name: Inamrinone
DrugBank: Amrinone (DB01427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indacrinone (−) enantiomer 10 mg with (+) enantiomer 80 mg (10/80)
Study: 7471605
Drug: Ticrynafen (T)
DrugBank: Tienilic acid (DB04831)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticrynafen (T) 250 mg daily
Study: 7471605
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 50 mg daily
Study: 26860492
Drug: Conventional ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ultrasound therapy for 6 minutes at 1.5 Watt/cm2 dose with 1 MHz frequency for 15 days
Study: 23320967
Drug: Intravenous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous epoetin (500 U/kg, 2 doses, 24 hours apart)
Study: 19353740
Drug: Debio 025
Normalized name: DEBIO-1347
DrugBank: DEBIO-1347 (DB12903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debio 025 600 mg/day + PEG IFN-alpha2a 180 microg/week
Study: 19353740
Drug: Debio 025
Normalized name: DEBIO-1347
DrugBank: DEBIO-1347 (DB12903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debio 025 1000 mg/day + PEG IFN-alpha2a 180 microg/week
Study: 19353740
Drug: Debio 025
Normalized name: DEBIO-1347
DrugBank: DEBIO-1347 (DB12903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debio 025 1000 mg/day (monotherapy)
Study: 19353740
Drug: PEG IFN-alpha2a
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG IFN-alpha2a 180 microg/week (monotherapy)
Study: 17868953
Drug: High fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fat flavored cream cheese (orange or banana)
Study: 17868953
Drug: Low fat
Normalized name: Low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fat flavored cream cheese (orange or banana)
Study: 15497297
Drug: Computer-assisted injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted injection system (Wand Plus)
Study: 11556573
Drug: HA1 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA1 (500 mg three times daily for 3 days, total dose: 4,500 mg)
Study: 11556573
Drug: HA2 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA2 (500 mg three times daily for the first and the third day, total dose: 3,000 mg)
Study: 11556573
Drug: HA3 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA3 (500 mg three times for one day followed by 500 mg once daily for 7 days, total dose: 4,500 mg)
Study: 9577350
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate 1200 micrograms buccal spray
Study: 2905188
Drug: Chemotherapy (5‐fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (5‐fluorouracil (FU) and 1‐(2‐chloroethyl)‐3‐(4‐methylcyclohexil)‐1‐nitrosourea (Me‐CCNU) after surgery
Study: 2905188
Drug: Chemo‐immunotherapy (FU,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo‐immunotherapy (FU, Me‐CCNU and levamisole) after surgery
Study: 30753662
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus OH4L (Oral Health 4 Life)
Study: 23782457
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 1 g over 10 minutes followed by 1 g over 8 hours
Study: 11913275
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 15% hydrogen peroxide in-office treatment and 10% carbamide peroxide take-home treatment
Study: 9393426
Drug: Spectra-System implants
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectra-System implants (HA-coated cylinders)
Study: 9393426
Drug: Spectra-System implants
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectra-System implants (titanium alloy baskets)
Study: 25428762
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg once weekly for 8 weeks
Study: 20580422
Drug: Exenatide 2
Normalized name: exenatide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 2 mg injected once weekly
Study: 20580422
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg oral once daily
Study: 20580422
Drug: Pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 45 mg oral once daily
Study: 18211120
Drug: Dobutamine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine at a dose of 2.5 microg/kg/min
Study: 18211120
Drug: Dobutamine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine at a dose of 5 microg/kg/min
Study: 18211120
Drug: Dobutamine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine at a dose of 10 microg/kg/min
Study: 16630938
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (polymerized extract)
Study: 28673384
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy (TRT) for 24 weeks
Study: 21143499
Drug: Atracurium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.5 mg kg(‐1) ideal body weight
Study: 21143499
Drug: Atracurium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.5 mg kg(‐1) total body weight
Study: 16550242
Drug: Outpatient family-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient family-based therapy (without FMI)
Study: 10750628
Drug: Functional Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional Insulin Treatment (FIT)
Study: 10780123
Drug: Nicotine transdermal
Normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine transdermal patch (21 mg)
Study: 1394752
Drug: Ketorolac (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (1 mg.kg‐1)
Study: 1394752
Drug: Acetaminophen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (10 mg.kg‐1)
Study: 1394752
Drug: Saline (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.1 ml.kg‐1)
Study: 29769831
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g Specific Collagen Peptides (SCP)
Study: 29769831
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g Placebo (Maltodextrin)
Study: 22108101
Drug: Vacuum-cast Co-Cr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum-cast Co-Cr (CC) with Ketac Cem Plus (KC)
Study: 22108101
Drug: Vacuum-cast Co-Cr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum-cast Co-Cr (CC) with Panavia F 2.0 (PF)
Study: 22108101
Drug: Vacuum-cast Co-Cr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum-cast Co-Cr (CC) with RelyX Unicem 2 Automix (RXU)
Study: 16089139
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of Sodium hyaluronate (SH) plus external application of Sanhua ointment (SHO)
Study: 16089139
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of Sodium hyaluronate (SH)
Study: 12145036
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline (NS) solution
Study: 2249121
Drug: Cephalosporin antibiotic
Normalized name: Cephalosporium roseum
DrugBank: Cephalosporium roseum (DB10932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalosporin antibiotic prophylaxis
Study: 7028069
Drug: Inoculation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inoculation with an autologous irradiated suspension of tumour cells combined with a small dose of C. parvum given intradermally during convalescence
Study: 18551295
Drug: Supplementation with
Normalized name: Similac For Supplementation with Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with 12 mg lutein and 1 mg zeaxanthin once per day (Ocuvite lutein) for 6 months
Study: 17645482
Drug: High-dose pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pantoprazole (80 mg + 8 mg/h)
Study: 17645482
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg q.d.
Study: 15738857
Drug: Self-help cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-help cognitive-behavioral therapy (CBT)
Study: 11158186
Drug: Nonpeptidic MMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpeptidic MMP inhibitors
Study: 7962442
Drug: Investigated for
Normalized name: INVESTIGATIONAL DRUGS FOR CONSTIPATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigated for antiphospholipid antibodies (APA), polycystic ovaries (PCO), hypersecretion of luteinizing hormone (LH), and chromosome abnormalities.
Study: 3311439
Drug: Two-tablet regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-tablet regimen (500 mg mefloquine, 1000 mg sulfadoxine, 50 mg pyrimethamine)
Study: 3311439
Drug: Three-tablet regimen
Normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-tablet regimen (750 mg mefloquine, 1500 mg sulfadoxine, 75 mg pyrimethamine)
Study: 31898521
Drug: ATRA-RIF (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATRA-RIF (oral arsenic realgar-indigo naturalis formula)
Study: 31898521
Drug: ATRA-ATO (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATRA-ATO (intravenous arsenic trioxide)
Study: 26279077
Drug: Midazolam (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (exact dosage not specified for group M1)
Study: 23776445
Drug: Ketamine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine administration during memory testing after Pavlovian fear conditioning
Study: 23776445
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration during memory testing after Pavlovian fear conditioning
Study: 19450052
Drug: Chronic oral
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic oral anticoagulation (e.g., warfarin or dicoumarol)
Study: 19450052
Drug: Oral antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antiplatelet agents
Study: 11240956
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of killed Mycobacterium vaccae (SRL 172)
Study: 11240956
Drug: Placebo (buffer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (buffer solution)
Study: 9259191
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (48-hour infusion)
Study: 9259191
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (48-hour infusion) in elderly patients (> 70 years)
Study: 31087093
Drug: Digital behavioral
Normalized name: AspyreRx Digital Behavioral Therapeutic Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital behavioral pain medicine intervention (MSS)
Study: 25673148
Drug: Diphenhydramine-containing medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine-containing medication (25 mg diphenhydramine, 10 mg phenylephrine)
Study: 25673148
Drug: Dextromethorphan syrup
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan syrup (30 mg)